Abbott Laboratories (NYSE:ABT) Shares Sold by NTV Asset Management LLC

NTV Asset Management LLC lowered its holdings in Abbott Laboratories (NYSE:ABT) by 4.7% during the 1st quarter, Holdings Channel reports. The firm owned 40,164 shares of the healthcare product maker’s stock after selling 2,000 shares during the period. NTV Asset Management LLC’s holdings in Abbott Laboratories were worth $3,211,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also bought and sold shares of ABT. 1 North Wealth Services LLC bought a new stake in shares of Abbott Laboratories in the fourth quarter valued at $33,000. Beacon Capital Management Inc. bought a new stake in shares of Abbott Laboratories in the first quarter valued at $38,000. Investors Research Corp bought a new stake in shares of Abbott Laboratories during the 1st quarter valued at $44,000. WP Advisors LLC bought a new stake in shares of Abbott Laboratories during the 1st quarter valued at $46,000. Finally, Exane Derivatives bought a new stake in shares of Abbott Laboratories during the 4th quarter valued at $42,000. 73.42% of the stock is currently owned by institutional investors and hedge funds.

A number of analysts recently issued reports on ABT shares. Zacks Investment Research upgraded Abbott Laboratories from a “hold” rating to a “buy” rating and set a $85.00 price objective on the stock in a research note on Monday, May 20th. Royal Bank of Canada boosted their price objective on Abbott Laboratories to $82.00 and gave the company a “buy” rating in a research note on Monday, April 15th. They noted that the move was a valuation call. Wells Fargo & Co reiterated a “buy” rating on shares of Abbott Laboratories in a research note on Thursday, March 14th. Barclays set a $84.00 price objective on Abbott Laboratories and gave the company a “buy” rating in a research note on Friday, March 8th. Finally, William Blair reiterated an “outperform” rating on shares of Abbott Laboratories in a research note on Thursday, April 18th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and fifteen have issued a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $80.24.



In other news, SVP Jaime Contreras sold 82,732 shares of the company’s stock in a transaction dated Thursday, April 25th. The stock was sold at an average price of $70.00, for a total value of $5,791,240.00. Following the completion of the transaction, the senior vice president now directly owns 80,722 shares in the company, valued at approximately $5,650,540. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Joseph J. Manning sold 5,613 shares of the company’s stock in a transaction dated Wednesday, March 20th. The stock was sold at an average price of $79.58, for a total value of $446,682.54. Following the completion of the transaction, the insider now owns 56,029 shares of the company’s stock, valued at $4,458,787.82. The disclosure for this sale can be found here. Insiders sold a total of 980,493 shares of company stock worth $74,796,843 over the last 90 days. Corporate insiders own 0.70% of the company’s stock.

NYSE ABT traded up $0.44 during trading on Wednesday, reaching $81.56. The company’s stock had a trading volume of 364,457 shares, compared to its average volume of 5,821,210. The firm has a market capitalization of $142.44 billion, a P/E ratio of 28.32, a P/E/G ratio of 2.27 and a beta of 1.08. The company has a quick ratio of 1.13, a current ratio of 1.58 and a debt-to-equity ratio of 0.61. Abbott Laboratories has a one year low of $60.31 and a one year high of $82.00.

Abbott Laboratories (NYSE:ABT) last announced its earnings results on Wednesday, April 17th. The healthcare product maker reported $0.63 earnings per share for the quarter, topping analysts’ consensus estimates of $0.61 by $0.02. The business had revenue of $7.54 billion for the quarter, compared to analyst estimates of $7.49 billion. Abbott Laboratories had a return on equity of 16.86% and a net margin of 8.53%. The company’s quarterly revenue was up 2.0% compared to the same quarter last year. During the same period in the prior year, the company earned $0.59 EPS. As a group, research analysts anticipate that Abbott Laboratories will post 3.22 EPS for the current fiscal year.

WARNING: This report was first published by Dakota Financial News and is the sole property of of Dakota Financial News. If you are viewing this report on another domain, it was stolen and reposted in violation of US & international trademark and copyright law. The original version of this report can be accessed at https://dakotafinancialnews.com/2019/06/12/abbott-laboratories-nyseabt-shares-sold-by-ntv-asset-management-llc.html.

About Abbott Laboratories

Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. The company's Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptom; gynecological disorder; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraine; and anti-infective clarithromycin, as well as provides influenza vaccines and products that regulate physiological rhythm of the colon.

Recommended Story: Why is a lock-up period needed for an IPO?

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT).

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.